The Claim
In adults with type 2 diabetes and chronic kidney disease, weekly administration of semaglutide at 1.0 mg reduces the risk of death from cardiovascular causes by 29% compared to placebo, with a hazard ratio of 0.71 (95% CI, 0.56 to 0.89), over a median follow-up of 3.4 years.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults with type 2 diabetes and chronic kidney disease, taking a weekly 1.0 mg dose of semaglutide is associated with a 29% lower risk of dying from cardiovascular causes compared to taking a placebo over approximately 3.4 years.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease, weekly semaglutide at 1.0 mg reduces the risk of death from cardiovascular causes by 29% compared to placebo, with a hazard ratio of 0.71 (95% CI, 0.56 to 0.89), over a median follow-up of 3.4 years.
Semaglutide lowers blood sugar and reduces fat in the liver and muscles, which decreases stress on the heart and kidneys. This allows the kidneys to filter blood more efficiently and lowers blood pressure, reducing strain on blood vessels and preventing heart failure and fatal heart rhythms.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
In people with type 2 diabetes and kidney disease, taking a weekly shot of semaglutide lowered their chance of dying from heart problems by about 29% compared to those who didn’t take it, over about 3.4 years.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.